AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

BioNTech SE (BNTX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

122.19

2.36 (1.97%)

At close: Feb 18, 2025, 3:59 PM

122.75

0.46%

After-hours: Feb 18, 2025, 04:15 PM EST

undefined% (undefined)

Bid	119.5
Market Cap	29.29B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.01
PE Ratio (ttm)	-60.79
Forward PE	n/a
Analyst	Buy

Ask	123.3
Volume	534,518
Avg. Volume (20D)	729,000
Open	120.45
Previous Close	119.83
Day's Range	118.52 - 124.49
52-Week Range	76.53 - 131.49
Beta	undefined

About BNTX

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for tripl...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 10, 2019

Employees 6,133

Stock Exchange NASDAQ

Ticker Symbol BNTX

Website https://www.biontech.de

Full Company Profile

Analyst Forecast

According to 15 analyst ratings, the average rating for BNTX stock is "Buy." The 12-month stock price forecast is $145, which is an increase of 18.67% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

BioNTech SE is scheduled to release its earnings on Mar 19, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+4.47%

Shares of vaccine stocks are trading higher as the... Unlock content with Pro Subscription

2 weeks ago

-2.24%

Shares of vaccine stocks are trading lower after the Senate Finance Committee voted to advance Robert F. Kennedy Jr.'s nomination to the Senate floor.

News

6 days ago · zacks.com

What Makes BioNTech (BNTX) a New Buy Stock

BioNTech (BNTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2 weeks ago · reuters.com

Vaccine, packaged food stocks fall as Kennedy moves closer to health secretary job

Shares of vaccine makers and packaged food companies fell on Tuesday after President Donald Trump's pick for U.S. health secretary, Robert F. Kennedy Jr., moved closer to the job after a favorable vot...

2 weeks ago · cnbc.com

Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary

Shares of vaccine companies fell after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services to the full chamber.

4 weeks ago · fool.com

3 Dirt-Cheap Stocks to Buy in a Market That's Priced for Perfection

How expensive is the stock market right now? The S&P 500 Shiller CAPE ratio is near its second-highest level ever.

1 month ago · zacks.com

Wall Street Analysts Predict a 25.59% Upside in BioNTech (BNTX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 25.6% in BioNTech (BNTX). While the effectiveness of this highly sought-after metric is questionable, the posit...

1 month ago · seekingalpha.com

Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

1 month ago · benzinga.com

BioNTech Positioned For Solid Growth Amid Oncology Transition: Analyst

On Thursday, Truist initiated coverage on BioNTech SE BNTX, a famed COVID-19 vaccine maker, in collaboration with Pfizer Inc PFE.

1 month ago · https://thefly.com

BioNTech initiated with a Buy at Truist

Truist initiated coverage of BioNTech with a Buy rating and $172 price target. BioNTech is an oncology company "at heart, even though it was the COVID vaccine that made it a household name," the analy...

1 month ago · fool.com

5 Predictions for the Stock Market in 2025 -- and Which Stocks Will Soar the Most If They're Right

Nearly one year ago, I made four predictions about the stock market in 2024. I thought the S&P 500 would generate positive returns but lower than in 2023.

1 month ago · reuters.com

BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties

BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University of Pennyslvania over the payment of royalties related to its COVID-19 vaccin...

Load More News